Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
SCH-48461
ID: ALA23541
Max Phase: Preclinical
Molecular Formula: C26H27NO3
Molecular Weight: 401.51
Molecule Type: Small molecule
Associated Items:
ID: ALA23541
Max Phase: Preclinical
Molecular Formula: C26H27NO3
Molecular Weight: 401.51
Molecule Type: Small molecule
Associated Items:
Synonyms (2): SCH-47949 | SCH-48461
Synonyms from Alternative Forms(2):
Canonical SMILES: COc1ccc([C@@H]2[C@@H](CCCc3ccccc3)C(=O)N2c2ccc(OC)cc2)cc1
Standard InChI: InChI=1S/C26H27NO3/c1-29-22-15-11-20(12-16-22)25-24(10-6-9-19-7-4-3-5-8-19)26(28)27(25)21-13-17-23(30-2)18-14-21/h3-5,7-8,11-18,24-25H,6,9-10H2,1-2H3/t24-,25-/m1/s1
Standard InChI Key: IMNTVVOUWFPRSB-JWQCQUIFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 401.51 | Molecular Weight (Monoisotopic): 401.1991 | AlogP: 5.43 | #Rotatable Bonds: 8 |
Polar Surface Area: 38.77 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 5.49 | CX LogD: 5.49 |
Aromatic Rings: 3 | Heavy Atoms: 30 | QED Weighted: 0.47 | Np Likeness Score: -0.02 |
1. Dugar S, Yumibe N, Clader JW, Vizziano M, Huie K, Van Heek M, Compton DS, Davis HR. (1996) Metabolism and structure activity data based drug design: discovery of () SCH 53079 an analog of the potent cholesterol absorption inhibitor () SCH 48461, 6 (11): [10.1016/0960-894X(96)00214-4] |
2. Dugar S, Yumibe N, Clader JW, Vizziano M, Huie K, Van Heek M, Compton DS, Davis HR. (1996) Metabolism and structure activity data based drug design: discovery of () SCH 53079 an analog of the potent cholesterol absorption inhibitor () SCH 48461, 6 (11): [10.1016/0960-894X(96)00214-4] |
3. Burnett DA, Caplen MA, Davis HR, Burrier RE, Clader JW.. (1994) 2-Azetidinones as inhibitors of cholesterol absorption., 37 (12): [PMID:8021912] [10.1021/jm00038a001] |
4. Burnett DA, Caplen MA, Davis HR, Burrier RE, Clader JW.. (1994) 2-Azetidinones as inhibitors of cholesterol absorption., 37 (12): [PMID:8021912] [10.1021/jm00038a001] |
5. Burnett DA, Caplen MA, Davis HR, Burrier RE, Clader JW.. (1994) 2-Azetidinones as inhibitors of cholesterol absorption., 37 (12): [PMID:8021912] [10.1021/jm00038a001] |
6. McKittrick BA, Ma K, Dugar S, Clader JW, Davis H, Czarniecki M, McPhail AT. (1996) Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorption inhibitors, 6 (16): [10.1016/0960-894X(96)00347-2] |
7. Dugar S, Kirkup MP, Clader JW, Lin S, Rizvi R, Snow ME, Davis HR, McCombie SW. (1995) Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH 484611, 5 (24): [10.1016/0960-894X(95)00516-6] |
8. Dugar S, Kirkup MP, Clader JW, Lin S, Rizvi R, Snow ME, Davis HR, McCombie SW. (1995) Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH 484611, 5 (24): [10.1016/0960-894X(95)00516-6] |
9. Burnett DA, Caplen MA, Domalski MS, Browne ME, Davis HR, Clader JW.. (2002) Synthesis of iodinated biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors., 12 (3): [PMID:11814785] [10.1016/s0960-894x(01)00750-8] |
10. Vaccaro WD, Davis HR.. (1998) Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar., 8 (3): [PMID:9871676] [10.1016/s0960-894x(98)00008-0] |
11. Burnett DA, Caplen MA, Browne ME, Zhau H, Altmann SW, Davis HR, Clader JW.. (2002) Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors., 12 (3): [PMID:11814786] [10.1016/s0960-894x(01)00752-1] |
12. Vaccaro WD, Sher R, Davis HR.. (1998) Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors., 8 (3): [PMID:9871677] [10.1016/s0960-894x(98)00009-2] |
13. Vaccaro WD, Sher R, Davis HR.. (1998) Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors., 8 (3): [PMID:9871677] [10.1016/s0960-894x(98)00009-2] |
14. Clader JW, Burnett DA, Caplen MA, Domalski MS, Dugar S, Vaccaro W, Sher R, Browne ME, Zhao H, Burrier RE, Salisbury B, Davis HR.. (1996) 2-Azetidinone cholesterol absorption inhibitors: structure-activity relationships on the heterocyclic nucleus., 39 (19): [PMID:8809157] [10.1021/jm960405n] |
15. Vaccaro WD, Sher R, Davis HR.. (1998) Sugar-substituted 2-azetidinones as cholesterol absorption inhibitors., 8 (1): [PMID:9871624] [10.1016/s0960-894x(97)10185-8] |
16. Dugar S, Clader JW, Chan TM, Davis H.. (1995) Substituted 2-azaspiro[5.3]nonan-1-ones as potent cholesterol absorption inhibitors: defining a binding conformation for SCH 48461., 38 (25): [PMID:8523398] [10.1021/jm00025a002] |
17. Dugar S, Clader JW, Chan TM, Davis H.. (1995) Substituted 2-azaspiro[5.3]nonan-1-ones as potent cholesterol absorption inhibitors: defining a binding conformation for SCH 48461., 38 (25): [PMID:8523398] [10.1021/jm00025a002] |
18. McKittrick BA, Ma K, Huie K, Yumibe N, Davis H, Clader JW, Czarniecki M, McPhail AT.. (1998) Synthesis of C3 heteroatom-substituted azetidinones that display potent cholesterol absorption inhibitory activity., 41 (5): [PMID:9513603] [10.1021/jm970676d] |
19. Rosenblum SB, Huynh T, Afonso A, Davis HR, Yumibe N, Clader JW, Burnett DA.. (1998) Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption., 41 (6): [PMID:9526571] [10.1021/jm970701f] |
20. Itzhak Y, Kalir A, Weissman BA, Cohen S.. (1981) New analgesic drugs derived from phencyclidine., 24 (5): [PMID:7241506] [10.1021/jm00137a004] |
21. Itzhak Y, Kalir A, Weissman BA, Cohen S.. (1981) New analgesic drugs derived from phencyclidine., 24 (5): [PMID:7241506] [10.1021/jm00137a004] |
22. Kvaernø L, Werder M, Hauser H, Carreira EM.. (2005) Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption., 48 (19): [PMID:16162006] [10.1021/jm050422p] |
23. Mehta PD, Sengar NP, Pathak AK.. (2010) 2-Azetidinone--a new profile of various pharmacological activities., 45 (12): [PMID:20970895] [10.1016/j.ejmech.2010.09.035] |
Source(1):